Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)
| Autor: | Morten H. Vatn, Tom Grotmol, Geir Hoff, G. Gondal, Michael Bretthauer, Espen Thiis-Evensen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adenoma
Male medicine.medical_specialty Colorectal cancer Colon Population Gastroenterology Sensitivity and Specificity Feces fluids and secretions Internal medicine medicine Biomarkers Tumor Humans Mass Screening education Sigmoidoscopy Mass screening education.field_of_study medicine.diagnostic_test business.industry Middle Aged medicine.disease Faecal calprotectin Occult digestive system diseases Neoplasm Proteins Occult Blood Female Calprotectin business Colorectal Neoplasms Leukocyte L1 Antigen Complex |
| Popis: | BACKGROUND: Screening for colorectal cancer (CRC) using guaiac based faecal occult blood tests (FOBT) has an estimated programme sensitivity of >60% but or =50 microg/g. RESULTS: The PhiCal test was positive in 24-27% of screenees whether they had no adenoma, low risk adenoma, or high risk adenoma. Ten (63%) of 16 CRCs gave a positive PhiCal test. The total positivity rate in this population was 25% for the PhiCal test compared with 12% for FlexSure OBT, with a sensitivity for advanced neoplasia of 27% and 35%, respectively. Specificity for "any neoplasia" was 76% for the PhiCal test and 90% for FlexSure OBT. CONCLUSIONS: In colorectal screening, the performance of the PhiCal test on a single spot from one stool sample was poorer than a single screening round with FlexSure OBT and cannot be recommended for population screening purposes. The findings indicate a place for FlexSure OBT in FOBT screening. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|